aea004

Andrew E. Aplin, PhD

Contact Dr. Aplin

233 South 10th Street
BLSB 522
Philadelphia, PA 19107

(215) 503-7296
(215) 923-9248 fax

Most Recent Peer-reviewed Publications

  1. Dysregulated GPCR signaling and therapeutic options in uveal melanoma
  2. Co-Targeting HGF/cMET Signaling with MEK Inhibitors in metastatic uveal melanoma
  3. An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma
  4. Triple jeopardy for people with albinism
  5. The melanoma field with dendritic roots
  6. The state of melanoma: challenges and opportunities
  7. Targeting mutant NRAS signaling pathways in melanoma
  8. Of Mice and melanoma: PDX system for modeling personalized medicine
  9. Welcome to the New Year!
  10. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRASĀ Melanoma
  11. Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization
  12. Fibroblast-derived neuregulin 1 promotes Compensatory ErbB3 receptor signaling in mutant BRAF melanoma
  13. PAX3 and FOXD3 promote CXCR4 expression in melanoma
  14. RAC1 P29S regulates PD-L1 expression in melanoma
  15. ErbB3-ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas
  16. Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer
  17. Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma
  18. Game of isoforms: PI3K Ī²-sparing inhibitor is coming
  19. The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox
  20. The value of thesis advisers